

# Atacicept in Multiple Glomerular Diseases

NCT06983028

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Vera Therapeutics, Inc.
<b>Enrollment</b>	200 participants

## Key Eligibility Criteria

---

### Inclusion (21)

- Weight of at least 40 kg
- On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease
- Systolic blood pressure  $\leq 160$  mmHg and diastolic blood pressure  $\leq 90$  mmHg at Screening. For participants aged  $\geq 10$  to  $< 18$  years, the average of 3 separate systolic and/or diastolic blood pressures  $< 95$ th percentile for age, gender, and height
- Diagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome
- For patients enrolling in IgAN cohorts (eligibility varies by cohort):  
... and 16 more (see full listing online)

### Exclusion (6)

- Evidence of rapidly progressive glomerulonephritis (loss of  $\geq 50\%$  of eGFR) within 3 months prior to and at Screening)
- Active viral or bacterial infections
- Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study
- Administration of live and live-attenuated vaccinations within 30 days prior to enrollment
- Known hypersensitivity to atacicept or any component of the formulated atacicept  
... and 1 more (see full listing online)

## Locations (1 total)

---

Vera Therapeutics, Brisbane, California, United States